Free Trial

Pacific Biosciences of California (PACB) Competitors

Pacific Biosciences of California logo
$0.94 -0.04 (-4.05%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$0.96 +0.02 (+1.65%)
As of 05:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PACB vs. HBIO, TMO, A, MTD, WAT, ILMN, TECH, BIO, CRL, and BRKR

Should you be buying Pacific Biosciences of California stock or one of its competitors? The main competitors of Pacific Biosciences of California include Harvard Bioscience (HBIO), Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Illumina (ILMN), Bio-Techne (TECH), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), and Bruker (BRKR). These companies are all part of the "life sciences tools & services" industry.

Pacific Biosciences of California vs.

Pacific Biosciences of California (NASDAQ:PACB) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, community ranking, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Pacific Biosciences of California presently has a consensus target price of $2.34, indicating a potential upside of 148.42%. Harvard Bioscience has a consensus target price of $3.00, indicating a potential upside of 808.54%. Given Harvard Bioscience's higher possible upside, analysts plainly believe Harvard Bioscience is more favorable than Pacific Biosciences of California.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacific Biosciences of California
0 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.56
Harvard Bioscience
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

80.9% of Harvard Bioscience shares are held by institutional investors. 2.5% of Pacific Biosciences of California shares are held by company insiders. Comparatively, 9.0% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Harvard Bioscience has a net margin of -14.57% compared to Pacific Biosciences of California's net margin of -200.40%. Harvard Bioscience's return on equity of -4.64% beat Pacific Biosciences of California's return on equity.

Company Net Margins Return on Equity Return on Assets
Pacific Biosciences of California-200.40% -42.89% -14.77%
Harvard Bioscience -14.57%-4.64%-2.40%

In the previous week, Pacific Biosciences of California had 5 more articles in the media than Harvard Bioscience. MarketBeat recorded 5 mentions for Pacific Biosciences of California and 0 mentions for Harvard Bioscience. Pacific Biosciences of California's average media sentiment score of 0.09 beat Harvard Bioscience's score of 0.00 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company Overall Sentiment
Pacific Biosciences of California Neutral
Harvard Bioscience Neutral

Harvard Bioscience has lower revenue, but higher earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacific Biosciences of California$152.36M1.85-$308.65M-$2.79-0.34
Harvard Bioscience$91.40M0.16-$3.41M-$1.32-0.25

Pacific Biosciences of California received 84 more outperform votes than Harvard Bioscience when rated by MarketBeat users. However, 71.15% of users gave Harvard Bioscience an outperform vote while only 66.37% of users gave Pacific Biosciences of California an outperform vote.

CompanyUnderperformOutperform
Pacific Biosciences of CaliforniaOutperform Votes
454
66.37%
Underperform Votes
230
33.63%
Harvard BioscienceOutperform Votes
370
71.15%
Underperform Votes
150
28.85%

Pacific Biosciences of California has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500.

Summary

Pacific Biosciences of California and Harvard Bioscience tied by winning 9 of the 18 factors compared between the two stocks.

Get Pacific Biosciences of California News Delivered to You Automatically

Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PACB vs. The Competition

MetricPacific Biosciences of CaliforniaAnalytical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$282.53M$4.31B$5.33B$8.39B
Dividend YieldN/A0.58%5.21%4.11%
P/E Ratio-0.5726.7026.7919.70
Price / Sales1.853.77393.69121.79
Price / CashN/A36.1738.2534.62
Price / Book0.361.546.774.50
Net Income-$308.65M-$84.30M$3.23B$248.22M
7 Day Performance-9.03%1.92%0.42%-0.80%
1 Month Performance-19.18%2.47%9.06%11.52%
1 Year Performance-51.47%-20.32%18.55%8.99%

Pacific Biosciences of California Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PACB
Pacific Biosciences of California
1.5904 of 5 stars
$0.94
-4.0%
$2.34
+148.4%
-49.1%$282.53M$152.36M-0.57730
HBIO
Harvard Bioscience
3.6194 of 5 stars
$0.35
+11.8%
$4.50
+1,178.0%
-90.0%$15.57M$94.14M-1.07490Analyst Forecast
High Trading Volume
TMO
Thermo Fisher Scientific
4.9932 of 5 stars
$432.16
+7.2%
$607.43
+40.6%
-32.3%$163.14B$42.90B26.14130,000Trending News
Dividend Announcement
Analyst Upgrade
Analyst Revision
A
Agilent Technologies
4.8366 of 5 stars
$115.53
+8.0%
$143.00
+23.8%
-28.2%$32.94B$6.51B26.5617,900Trending News
Upcoming Earnings
Dividend Announcement
Analyst Forecast
MTD
Mettler-Toledo International
4.4721 of 5 stars
$1,175.33
+8.7%
$1,296.13
+10.3%
-24.4%$24.43B$3.83B29.0018,000News Coverage
Positive News
Analyst Upgrade
WAT
Waters
3.9387 of 5 stars
$366.80
+6.6%
$390.19
+6.4%
-0.2%$21.83B$2.98B34.258,200Trending News
Analyst Upgrade
ILMN
Illumina
4.8012 of 5 stars
$81.57
+7.7%
$130.95
+60.5%
-25.0%$12.91B$4.37B-10.6211,500Positive News
Analyst Forecast
TECH
Bio-Techne
4.8427 of 5 stars
$53.90
+7.9%
$73.44
+36.3%
-43.0%$8.52B$1.21B54.443,000Positive News
Dividend Announcement
High Trading Volume
BIO
Bio-Rad Laboratories
4.7973 of 5 stars
$254.32
+6.6%
$327.40
+28.7%
-22.1%$7.12B$2.54B-3.918,200Positive News
CRL
Charles River Laboratories International
4.9025 of 5 stars
$143.06
+3.1%
$176.00
+23.0%
-38.2%$7.03B$4.02B953.7121,400Positive News
BRKR
Bruker
4.9301 of 5 stars
$40.26
+7.3%
$60.10
+49.3%
-53.6%$6.10B$3.37B52.978,520Dividend Announcement
Analyst Forecast
High Trading Volume

Related Companies and Tools


This page (NASDAQ:PACB) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners